A new trading day began on Monday, with Climb Bio Inc (NASDAQ: CLYM) stock price down -9.94% from the previous day of trading, before settling in for the closing price of $4.93. CLYM’s price has ranged from $1.05 to $5.05 over the past 52 weeks.
A company in the Healthcare sector has dropped its sales by -40.44% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 46.48%. With a float of $62.43 million, this company’s outstanding shares have now reached $68.18 million.
Climb Bio Inc (CLYM) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Climb Bio Inc is 8.44%, while institutional ownership is 45.75%. The most recent insider transaction that took place on Dec 11 ’25, was worth 464,556. In this transaction Director of this company bought 213,099 shares at a rate of $2.18, taking the stock ownership to the 3,294,856 shares. Before that another transaction happened on Dec 12 ’25, when Company’s Director bought 101,462 for $2.86, making the entire transaction worth $290,181. This insider now owns 3,396,318 shares in total.
Climb Bio Inc (CLYM) Latest Financial update
In its latest quarterly report, released on 12/31/2024, the company reported earnings of 0.04 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 46.48% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.57% during the next five years compared to -40.44% drop over the previous five years of trading.
Climb Bio Inc (NASDAQ: CLYM) Trading Performance Indicators
Here are Climb Bio Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 18.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.75, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.85 in one year’s time.
Technical Analysis of Climb Bio Inc (CLYM)
Let’s dig in a bit further. During the last 5-days, its volume was 0.92 million. That was better than the volume of 0.6 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 81.98%.
During the past 100 days, Climb Bio Inc’s (CLYM) raw stochastic average was set at 82.67%, which indicates a significant increase from 81.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.63 in the past 14 days, which was higher than the 0.22 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.46, while its 200-day Moving Average is $1.79. However, in the short run, Climb Bio Inc’s stock first resistance to watch stands at $4.78. Second resistance stands at $5.13. The third major resistance level sits at $5.35. If the price goes on to break the first support level at $4.22, it is likely to go to the next support level at $4.00. The third support level lies at $3.65 if the price breaches the second support level.
Climb Bio Inc (NASDAQ: CLYM) Key Stats
With a market capitalization of 302.74 million, the company has a total of 68,184K Shares Outstanding. Currently, annual sales are 0 K while annual income is -73,900 K. The company’s previous quarter sales were 0 K while its latest quarter income was -12,890 K.
